Johnson & Johnson
JNJ

$393.46 B
Marketcap
$163.45
Share price
Country
$0.62
Change (1 day)
$168.85
Year High
$143.13
Year Low

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

marketcap

P/E ratio for Johnson & Johnson (JNJ)

P/E ratio as of 2023: 11.30

According to Johnson & Johnson's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 11.30. At the end of 2022 the company had a P/E ratio of 25.73.

P/E ratio history for Johnson & Johnson from 1985 to 2023

PE ratio at the end of each year

Year P/E ratio
2023 11.30
2022 25.73
2021 21.60
2020 28.00
2019 25.30
2018 22.46
2017 288.31
2016 18.85
2015 17.97
2014 17.96
2013 18.82
2012 17.95
2011 18.47
2010 12.90
2009 14.55
2008 12.63
2007 18.18
2006 17.56
2005 17.18
2004 21.94
2003 21.14
2002 24.45
2001 31.60
2000 32.76
1999 33.05
1998 37.58
1997 26.45
1996 22.93
1995 22.99
1994 17.55
1993 16.51
1992 32.21
1991 26.02
1990 20.86
1989 18.47
1988 14.99
1987 15.34
1986 34.17
1985 15.67